Lastest Stories by Trey Thoelcke

Clorox has rewarded shareholders again with a quarterly dividend. As a Dividend Aristocrat, it is the epitome of a steady and reliable stock.
Warren Buffett recently boosted his stake in the newly independent Sirius XM. Biotech initial public offerings in the past week also prompted some huge insider buying.
Procter & Gamble has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and reliable stock.
While Nvidia stock looks like it may have plateaued, here are three less exciting stocks that could be worth more than it by 2030.
Here is a look at why companies split their stocks and why stock splits matter. Plus, upcoming stock splits to watch from Mangoceuticals, Pineapple Energy, 23andMe, and more.
Developments between Nvidia and major customer Meta this year bode well for both companies and their stocks. But is Wall Street on board?
Insider buying slowed ahead of the third-quarter earnings reporting season, but an IPO tempted one insider, and a repeat buyer returned to boost a stake.
These five candidates to be the best-performing growth stock over the next five years include biotech, energy, and software stocks.
Public offerings of stock and activist investor activity prompted some huge insider buying at an entertainment company, an airline, biotechs, and more.
Selecting stocks for the long haul can be a challenge. Here is what could be the best-performing stock in 2030 and why.
These five little-known perks to shopping at Home Depot can help consumers get more out of their shopping trips in this time of economic uncertainty.
A public offering of shares this past week prompted a huge purchase from a beneficial owner. Meanwhile, a couple of repeat buyers further boosted their stakes as well.
Apple was the first U.S. company valued at $1 trillion, then $3 trillion, but will it be first to have a $5 trillion market cap?
IPOs at three biotechs last week tempted insiders to make huge purchases of shares. This effect spilled over into buying at a couple of other biotechs as well.
Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what the company's prospects are for the next decade of growth.